Intech Investment Management LLC Grows Stake in ADMA Biologics, Inc. (NASDAQ:ADMA)

Intech Investment Management LLC boosted its position in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 78.3% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 110,756 shares of the biotechnology company's stock after acquiring an additional 48,636 shares during the period. Intech Investment Management LLC's holdings in ADMA Biologics were worth $1,899,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the business. Larson Financial Group LLC purchased a new stake in shares of ADMA Biologics in the third quarter valued at $31,000. GAMMA Investing LLC boosted its stake in ADMA Biologics by 106.6% in the 4th quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company's stock worth $32,000 after buying an additional 967 shares during the last quarter. National Bank of Canada FI purchased a new stake in ADMA Biologics in the 3rd quarter valued at about $35,000. Vision Financial Markets LLC purchased a new stake in ADMA Biologics in the 4th quarter valued at about $51,000. Finally, Harvest Fund Management Co. Ltd acquired a new position in shares of ADMA Biologics during the 3rd quarter valued at about $62,000. 75.68% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $25.00 price target on shares of ADMA Biologics in a research report on Tuesday, March 4th.

Remove Ads

ADMA Biologics Trading Down 0.5 %

NASDAQ:ADMA traded down $0.10 on Tuesday, hitting $20.22. 2,401,540 shares of the stock were exchanged, compared to its average volume of 3,363,541. The stock has a fifty day moving average of $16.84 and a 200-day moving average of $18.07. The stock has a market cap of $4.78 billion, a PE ratio of 72.21 and a beta of 0.60. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. ADMA Biologics, Inc. has a fifty-two week low of $5.90 and a fifty-two week high of $23.64.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.